Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical's Mezagitamab?
Mezagitamab is a monoclonal antibody commercialized by Takeda Pharmaceutical, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple...
Mezagitamab by Takeda Pharmaceutical for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase I for IgA Nephropathy (Berger's Disease). According to...
Mezagitamab by Takeda Pharmaceutical for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Mezagitamab by Takeda Pharmaceutical for Myasthenia Gravis: Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...
Mezagitamab by Takeda Pharmaceutical for Systemic Lupus Erythematosus: Likelihood of Approval
Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...